Innovate with Confidence – Discover our New Research Essentials

In Vitro and In Vivo Filovirus Models for Preclinical Development

IBT Bioservices provides validated in vitro and in vivo models for Ebola, Marburg, Sudan, and Bundibugyo viruses to accelerate antiviral and vaccine development. In addition to offering these robust translational models, we support major government programs and deliver comprehensive assay development services tailored to advance filovirus research, therapeutic discovery, and regulatory approval pipelines.

Filovirus Testing Capabilities (Ebola, Marburg, Sudan)

reagents

3 Virus Like Particles
1 ELISA Kit

41 Antibodies

24 Proteins

1 Pseudovirus & 2 Virus like particles

2 Pseudovirus & 1 Virus like particles

in vitro assays

ELISA

Pseudovirus Neutralization Testing

animals models

AG129 Mice

available strains

Mayinga/Zaire

Makona

Sudan (Gulu, Boniface)

Bundibugyo

Angola

Musoke

Ci67

RAVN/strong>

Gulu

Boniface

High-Throughput Filovirus Assays to Advance Lead Candidates

Whether you are ranking small-molecule entry inhibitors or characterizing vaccine-induced antibody responses across Ebola, Marburg, Sudan, and Bundibugyo, IBT Bioservices’ filovirus platform is built to sustain demanding discovery and preclinical timelines.

Advanced In Vivo Filovirus Efficacy Validation

Transitioning from in vitro screening to candidate selection requires translational animal models that recapitulate filovirus disease and protection. IBT Bioservices supports this step with rigorously characterized in vivo studies that integrate BSL-2 pseudo-filovirus models and BSL-4 live-virus partnerships for Ebola, Marburg, Sudan, and Bundibugyo programs.

1. AG129 Pseudo-Filovirus Mouse Model

IBT has developed lethal infections in Ag129 mice using pseudo-filoviruses, enabling survival, viral-load, and immunologic endpoints to be generated under BSL-2 conditions. This platform provides an efficient, cost-effective path to rank-order candidates and optimize dosing regimens before escalation to high-containment live-virus studies.

2.Complementary Filovirus Models and BSL‑4 Collaborations

To confirm efficacy against authentic filoviruses, IBT coordinates studies in additional murine and guinea pig models through established BSL‑4 collaborators, using clinically relevant Ebola and Marburg isolates. These integrated programs deliver robust in-vivo data packages with survival, virology, pathology, and immune readouts that support cross‑protection assessments and de‑risk advancement toward IND‑enabling development.